THE CHALLENGE
97% of cancer therapies fail during clinical testing, highlighting the urgent need to improve the oncology drug development process*. While some drugs are designed to inhibit certain cancer proteins, the mechanisms-of-action for many of these drugs have been misidentified†.
Without an accurate understanding of how cancer drugs actually work, patients will receive the wrong treatments - contributing to the unacceptably-high failure rate of new therapies. Meliora is bringing the latest genomic, computational, and machine learning techniques to bear to change this paradigm. We believe that identifying the true mechanisms-of-action of chemical compounds allows more accurate, effective, and rapid drug development.
OUR PLATFORM
Meliora Therapeutics is applying modern machine learning methods to develop a first-of-its-kind atlas of drug mechanisms and their impact on cancer biology.
We leverage this target-agnostic mechanism-of-action atlas to identify potent compounds that inhibit key cancer targets, ultimately allowing us to develop better cancer therapies.
